NASDAQ: KLRSKalaris Therapeutics Inc Stock
$2.13-0.10 (-4.48%)
Updated Oct 14, 2026
KLRS Price
$2.13
Fair Value Price
$6.33
Market Cap
$50.70M
52 Week Low
$2.11
52 Week High
$11.88
P/E
-1.05x
P/B
0.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$44.26M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.73
Operating Cash Flow
-$41M
Beta
1.4
Next Earnings
Nov 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KLRS Overview
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KLRS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KLRS
Ranked#235 of 459
Ranked#235 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.20 | A | |
| $7.36 | A | |
| $116.82 | A |
Be the first to know about important KLRS news, forecast changes, insider trades & much more!
KLRS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KLRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KLRS ($2.13) is undervalued by 66.34% relative to our estimate of its Fair Value price of $6.33 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KLRS ($2.13) is significantly undervalued by 66.34% relative to our estimate of its Fair Value price of $6.33 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KLRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KLRS due diligence checks available for Premium users.
Valuation
KLRS fair value
Fair Value of KLRS stock based on Discounted Cash Flow (DCF)
Price
$2.13
Fair Value
$6.33
Undervalued by
66.34%
KLRS ($2.13) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KLRS ($2.13) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KLRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KLRS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.05x
Industry
15.05x
Market
45.8x
KLRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.88x
Industry
4.92x
KLRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KLRS's financial health
Profit margin
Revenue
$0.0
Net Income
-$11.5M
Profit Margin
0%
KLRS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$99.5M
Liabilities
$41.9M
Debt to equity
0.73
KLRS's short-term assets ($95.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KLRS's short-term assets ($95.92M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KLRS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KLRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.0M
Investing
$20.2M
Financing
-$377.0k
KLRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KLRS vs Biotech Stocks
Kalaris Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.